Lipoprotein(a): The science behind the Risk Factor

Name: Lipoprotein(a): The science behind the Risk Factor - Cardio ThinkLab
Uploaded: 2024-05-06T13:30:04+08:00
Duration: 3400S
Description: In this webinar, experts from Australia discuss the association between Lipoprotein(a) levels and risk of cardiovascular disease.

Webinar

cardiovascular risk

lipoprotein(a)

Prof Stephen Nicholls Director, Victorian Heart Hospital and Victorian Heart Institute, Clayton, Australia

Assoc Prof David Sullivan Physician and Chemical Pathologist, Department of Clinical Biochemistry, Royal Prince Alfred Hospital, New South Wales, Australia

Assoc Prof Karam Kostner Director of Cardiology, Mater Public and Private Hospital, Brisbane, Australia

6 May 2024

Key Takeaways

Higher Lipoprotein(a) levels are associated with increased rate of CVD. The recent 2019 ESC guidelines recommend Lp(a) biomarker testing at least once in each adult person’s life.
Challenges to implementation of Lp(a) biomarker testing include access, feasibility, affordability and impact on outcomes.
Patients with elevated Lipoprotein(a) levels with elevated risk of CVD should be treated to reduce LDL levels.